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Abstract  
Cervical cancer lesions represent a major threat to the health of the women worldwide. Human Papillomavirus (HPV) is 
responsible for 99.7% of cervical cancer cases, the infectious etiology giving the possibility of preventing cervical cancer by 
vaccination. The most aggressive HPV types are 16 and 18, which cause about 70% of cases of invasive cancer. The vaccination is 
recommended to the girls aged 11-12. The diagnosis and the treatment of cervical preinvasive disease allow the doctor to prevent 
the development of the invasive disease. 
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Introduction
Cervical cancer and precancerous cervical lesions 
constitute a major health problem for the women. The 
clinical and molecular studies have identified the HPV as 
the main cause of cervical preneoplastic lesions and 
cervical cancer. Almost all cervical cancers contain 
genetic material from the high-risk HPV types. The 
screening has dramatically reduce the incidence of the 
cervical cancer. However, in the developing countries 
where the access to the medical services is poor, the 
cervical cancer has a very high incidence, being in the 
second place as a cancer related cause of death [1]. The 
treatment of preinvasive disease consists in ablative or 
excisional procedures, with approximately 90% of 
effectiveness, with low morbidity and costs, compared to 
the treatment of invasive disease. The preventive 
vaccination tries to eradicate the infection by protecting 
the young girls before the encounter with the virus. 
Pathogenesis 
The history of the HPV began in the seventies when 
zur Hausen isolated the type 6 from the warts lesions. 
Since then, HPV is recognised as the etiologic agent of 
the cervical cancer. Until now, there are over 40 viral 
strains implicated in the pathogenesis of cervical cancer. 
HPV belongs to the family of the Papovaviridae. The 
viral infection is a necessary factor for the appearance of 
the cervical neoplasia, but it is not enough, requiring also 
particular host and environmental factors. The HPV 
infection seems to be implicated in 99.7% of the cervical 
cancer. Virtually all cervical cancers (over 99%) contain 
the genes of high-risk HPV, especially 16, 18, 31 and 45. 
Most of HPV infections regress spontaneously, especially 
those in adolescents and young women [2]. 
There are over 200 types of HPV, divided in three 
categories: the high-risk types (generating HG-SIL lesions 
and invasive neoplasia) - 16, 18, 31, 33, 35, 45, 52, 56, 
58, 59, probably high-risk types – 26, 53, 66, 68, 73, 82 
and low-risk (moderate dysplasia and genital warts) - 6, 
11. 
The vaccine against the infection with HPV has made 
possible the cervical cancer primary prophylaxis. The 
secondary prophylaxis was found also very effective. The 
cervical dysplasia cure is accurately assessed by the 
combination of negative PAP smear and negative DNA-
HPV test. 
The majority of HPV infections are subclinical and 
transitory (>80% disappear within 2 years) due to the 
cellular immune response. After infection, HPV is latent 
for 2-12 months. The cellular immune response starts in 
about 3 months from inoculation of virus and eliminates or 
suppresses it down to undetected levels. 
In some subjects, the infection can cause warts 
(condyloma) and low-grade cervical lesions. Sometimes, 
in certain cases, the high risk HPV types (16, 18, 31, 45) Journal of Medicine and Life  Vol. 2, No.4, October-December 2009 
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can be persistent and progress to high-grade lesions and 
cervical cancer in a few years [3]. The mean interval of 
natural progression to invasive cancer is about 13 years. 
HPV infection means the viral particles replicate in 
the mature keratinocytes. Active infection occurs when 
the virus invades the basal epithelial layer. Persistency of 
infection means the HPV infected the stem epithelial cells. 
Viral replication needs the oncoproteins E6 and E7 which 
bind the tumor supressor genes p53 and pRB. The 
initiation of oncogenic process begins when viral DNA 
was integrated in the host genome [4]. Viral transmission 
is done particularly through sexual intercourse. Use of 
condoms lowers the risk of transmission, but doesn’t offer 
complete protection. 
Until the age of 50, it is estimated that over 80% of 
sexually active women became HPV infected at some 
moment in their lives. Approximately 75% of the new HPV 
infections appear between the ages 15 and 24. Most of 
these infections are transient and disappear 
spontaneously (70% at one year, 90% at 2 years for 
young women). HIV coinfection, which suppresses the 
cellular immune response, represents a severity factor. 
The time from the first HPV infection, persistency,  
preneoplastic lesions and cancer is estimated to be 13-15 
years. 
Diagnosis 
Diagnosis of preneoplastic lesions is based on 
cytology, colposcopy and the final diagnosis is 
established by histopathological examination of the tissue 
sample. 
Cytologic examination. Bethesda System 
The Bethesda System and its 2001 revisions aim to 
simplify Papanicolaou (Pap) smear reporting and to make 
it more reproducible. The main types of preneoplastic 
lesions described are: atypical squamous cells of 
undetermined significance (ASCUS); atypical squamous 
cells, cannot exclude high-grade squamous intraepithelial 
lesion (ASC-H); low-grade squamous intraepithelial lesion 
(LSIL), high-grade squamous intraepithelial lesion (HSIL), 
squamous cell carcinoma, atypical glandular cells (AGC), 
endocervical adenocarcinoma in situ (AIS) and 
adenocarcinoma [5]. 
 
 
 
 
 
Specimen type 
Conventional smear (Pap smear) 
Liquid-based preparation 
Specimen adequacy 
Satisfactory for evaluation 
Unsatisfactory for evaluation 
Interpretation of the results 
A. Negative for intraepithelial lesion or malignancy 
1. Microorganisms (Trichomonas, Candida, Gardnerella etc.) 
2. Other non-neoplastic findings (inflamation or reactive cellular changes; radiotherapy; IUD; atrophy, glandular cells 
status post hysterectomy) 
B. Other endometrial cells (in woman ≥40 years of age) 
C. Epithelial cell abnormalities: 
1. Squamous cell 
Atypical squamous cells (ASC) 
-  ASC of undetermined significance (ASC-US) 
-  ASC, cannot exclude high-grade squamous intraepithelial lesion (ASC-H) 
Low-grade squamous intraepithelial lesion (LSIL) 
-  encompassing: HPV, mild dysplasia, and CIN 
High-grade squamous intraepithelial lesion (HSIL) 
-  encompassing: moderate and severe dysplasia, carcinoma in situ, CIN II, and CIN III 
Squamous cell carcinoma  
2. Glandular cell 
Atypical glandular cells (AGC) 
-  specify endocervical, endometrial, or glandular cells not otherwise specified (NOS) 
Atypical glandular cells, favor neoplastic 
-  specify endocervical or not otherwise specified (NOS) 
Endocervical adenocarcinoma in situ (AIS) 
Adenocarcinoma 
D.Other malignant neoplasms 
Table. 1. The 2001 Bethesda System for Reporting Cervical Cytologic Diagnoses Journal of Medicine and Life  Vol. 2, No.4, October-December 2009 
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Colposcopy 
Colposcopy identifies a series of lesions associated 
with preneoplastic cervical lesions (acetowhite changes, 
leukoplakia, punctation and mosaic). Acetowhite changes 
represents the white zone that appears after treatement of 
the cervix with acetic acid (3-5%). The acetic acid does 
not affect the mature epithelium rich in glycogen, but 
colours the dysplasic epithelium in white because of the 
high protein content. The metaplasic epitelium is very thin 
- unlike CIN which becomes white - so it will become gray 
and translucent. Leukoplakia (white epithelium after acetic 
acid aplication) –hyperkeratosis -  is the most frequent 
cause of HPV infection. Punctations (a zone of red dots - 
dilated capilaires which ends to the surface) in well 
circumscribed areas indicates an abnormal epithelium, 
most frequent CIN. Mosaicism (an abnormal pattern of 
interconnecting small blood vessels) is associated with 
high grade lesions – CINII/III [6]. 
 
Histopathology 
In mild dysplasia (CIN I) only few cells in the basal 
third of the epitelium are abnormal, while in moderate 
dysplasia (CIN II) the abnormal cells involve about 2/3 of 
the thickness of the surface lining of the cervix. In severe 
dysplasia  or carcinoma in-situ (CIN III) the entire 
thickness of the basal epithelium is abnormal. 
Spontaneous regression rate of CIN I is about 60-85%. 
The regression usually solves in about 2 years. All CIN II 
and CIN III lesions need treatment. The progression CIN 
II to CIS is 20% and invasion in about 5% of patients [7]. 
 
Vaccination 
The characteristic of the cervical cancer is its 
infectious etiology and the possibility of preventing the 
cancer through vaccination against HPV, the central 
factor implicated in pathogenesis. 
Speaking about prevention strategies, we can 
separate them in three categories: 
1. Primary prevention – prophylactic vaccination 
and modification of risk factors (behavioural factors and at 
risk sexual behaviours). 
2. Secondary prevention – early detection and 
treatment of the preneoplastic lesions (screening 
programs for CIN and HPV, excisional therapy, 
therapeutic vaccines, retinoids, immune modulators). 
3. Tertiary prevention – cervical cancer treatment 
and postsurgical follow-up (surgery, chemotherapy, 
radiotherapy and posttreatment follow-up). 
Two vaccines are at the moment licensed in USA and 
Europe: a bivalent one and a tetravalent one. Both of 
them are using the same principle: they contain particles 
identical to the viral capsid, without any viral DNA, lacking 
the infectivity or the oncological risk. The empty protein 
shells are composed of major L1 capsid proteins which 
are specific for each HPV type [8]. The tetravalent vaccine 
protects against HPV types 6, 11, 16 and 18 and the 
bivalent vaccines against types 16 and 18. The vaccines 
are given as three intramuscular shots at 0, 2 and 6 
months for the tetravalent vaccine and at 0, 1 and 6 
months for the bivalent vaccine. The side effects reported 
have been minor, consisting of mild local and systemic 
reactions. Fever has been the most commonly systemic 
reaction and pain, the most commonly local reaction. 
Other adverse reactions reported were locally erythema 
and edema and nausea and headaches [9]. Both 
vaccines are effective; at over 5 years from the beginning 
of the vaccination, the effectiveness of both vaccines was 
close to 100% in preventing persistent infection with HPV 
type 16 and 18 and CIN II and III associated to these 
types. The tetravalent vaccine protects also against 
genital warts, vaginal and vulvar intraepithelial neoplasia 
[10]. The vaccination is recommended for the girls ages 
11-12 and could begin from the 9 years of age. The 
vaccination is also recommended for the patients between 
13 and 18 years old for the completion of the vaccination 
scheme. Untill now, proof of efficacy lacks for the 
vaccination of women aged 19 to 26. Screening for 
preneoplastic lesions and cervical cancer must continue 
in the general population, but also in the vaccinated 
population [11,12]. 
 
The management of the precursor lesions of the 
cervical cancer 
There are a few categories for whom the 
management is a little bit different because of their 
characteristics: adolescents (aged <20), pregnant women, 
postmenopausal women and immune-compromised 
women. Adolescents have a higher prevalence of the 
HPV infection, more frequent minor lesions and a very low 
risk of cervical invasive cancer compared to older 
patients, because most of the HPV infections disappear 
spontaneously in 2 years of time and have little short term 
significance. Therefore, the colposcopy should not be 
performed as a first line investigation. During pregnancy, 
endocervical curettage is forbidden, while the colposcopic 
guided biopsy is indicated for HSIL or when invasive 
cancer is suspected. Colposcopy is a reasonable 
investigation for the low risk pregnant women [13]. 
 
ASC-US 
High risk DNA-HPV testing, repeated cervical smear 
and colposcopy are all acceptable methods in the 
management of ASC-US lesions for the patients aged 
over 20 years. The patients ASC-US and DNA- HPV 
negative for the high risk types will be followed up at 12 
months. Patients with ASC-US and DNA-HPV positive 
should be treated as the patients with LSIL and evaluated 
by colposcopy. Endocervical curettage is preferred for the 
patients without colposcopic lesions or with unsatisfactory 
colposcopy. The management after colposcopy for ASC-
US/DNA-HPV positive patients, which do not have CIN 
diagnosed, consists in repeating the DNA-HPV test every Journal of Medicine and Life  Vol. 2, No.4, October-December 2009 
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12 months or repeating Pap smear every 6-12 months. 
DNA-HPV testing is not recommended earlier than 12 
months. Repeating cytology at 6 months is indicated until 
two consecutive negative results are obtained, then 
normal follow-up is recommended [8]. Colposcopy is 
recommended for patients with ASC-US or severe lesions 
at the repeated testing, without taking into account DNA- 
HPV status. 
Excisional diagnostic procedures are not 
recommended in the treatment of the patients with ASC-
US as an initial diagnosis, in the absence of CIN II/III 
histopathological diagnosis. 
 
ASCH  
The management of ASC-H implies the colposcopic 
evaluation from the beginning. If there is an evident 
colposcopic lesion, biopsy is recommended. For the 
patients without CIN II/III, the follow-up is acceptable by 
testing DNA-HPV every 12 months or repeating cytology 
every 6-12 months. If DNA-HPV testing is negative or two 
consecutive smears are negative, return to normal follow-
up is recommended. 
 
LSIL 
Colposcopy is recommended from the beginning for 
LSIL cytology. Endocervical curettage is preferred for the 
patients without colposcopic lesions or with unsatisfactory 
colposcopy. After colposcopy, for the patients with LSIL 
without histopathological CIN II/III, the recommended 
attitude is DNA-HPV testing at every 12 months or 
repeated cytological at 6-12 months. If the DNA-HPV 
testing or two successive cytological results are negative, 
normal follow-up is recommended. If HPV DNA tesing is 
positive or at least one cytological testing result is ASC-
US or higher, colposcopy have to be repeted. 
 
HSIL 
For HSIL lesions the risk for preinvasive disease is 
70-75% and for invasive disease is 1-2% [14]. So, 
colposcopy and biopsy are indicated ab initio. 
Endocervical evaluation (cytological, colposcopic or 
curettage) is mandatory, excepting the case when the 
excisional biopsy is taking into account. When colposcopy 
and endocervical cytological evaluation are negative, the 
diagnosis of HSIL is reconsidered. If the cytological result 
persists, excisional biopsy is recommended [14]. 
 
AGC 
Fractioned curettage (endocervical and endometrial) 
and colposcopy are recommended for the patients with 
AGC/AIS aged over 40 years old. Also endometrial 
curettage is to be done for the patients over 40 years old 
with risk factors for endometrial cancer. DNA-HPV testing 
is not routinely recommended. The most frequent viral 
types associated with endocervical adenocarcinoma are 
16, 18 and 45. 
Surgical treatment 
Precursor lesions of the cervical cancer can be 
treated through local distructive methods or excision. The 
local distructive methods (cryotherapy, electrodiathermy, 
laser vaporization) are no more a standard therapy 
because they do not allow the histopathological 
examination of the specimen. 
Excisional methods are loop/needle electrosurgical 
excision procedures, laser excision and cold knife 
excision. Loop electrosurgical excision (LEEP) can be 
done as an outpatient procedure, with local anesthesia. 
Needle electrosurgical excision of the transformation zone 
(NETZ) has the advantage of excising the lesion as a 
single piece, easier to be histopathologically evaluated 
and allowing the optimal tailoring of the specimen to be 
resected (height and wide) [14]. The use of cold knife 
leaves the borders of the specimen clean, but the 
complications are more frequent. Postoperative 
complications are hemorrhage, infections and cervical 
stenosis, as well as the rise of the risk for premature 
delivery in a subsequent pregnancy (if the specimen 
height is over 1.5 cm). The frequency of these 
complications is very low [15,16]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cold knife conization has the advantage of 
preserving the specimen intact for the histopathological 
examination and allowing for a good evaluation of the 
tissue margins. Although the cure rate is the same as with 
the use of electrocautery, the frequency of complications 
is double. 
Total histerectomy, abdominal or vaginal, represents 
a very rare indication in the therapy of precursor lesions of 
the cervical cancer. It is the choice when the lesion wasn’t 
totally resected, persistent abnormal Pap smear, lesion 
extended to the vaginal vault, associated gynecologic 
pathology, difficult follow-up after conization. 
Fig. 1. Needle excision of the transformation zone (NETZ). Journal of Medicine and Life  Vol. 2, No.4, October-December 2009 
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